key: cord-0720103-1aohnzyy
authors: Stein, Richard A.; Young, Lauren M.
title: From ACE2 to COVID-19: A multiorgan endothelial disease
date: 2020-09-05
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.08.083
sha: 69965880babaf62d31c833ff5843a1dc4c901730
doc_id: 720103
cord_uid: 1aohnzyy

nan

From ACE2 to COVID-19: A multiorgan endothelial disease To date, three coronaviruses have caused major human outbreaks in the 21st century. In 2002-2003, SARS-CoV (the severe acute respiratory syndrome-associated coronavirus) caused 8447 reported SARS cases and 813 deaths, with a case fatality rate of $10% (Park, 2020; Cleri et al., 2010; Lin et al., 2006; Satija and Lal, 2007) . MERS-CoV (the Middle East respiratory syndrome coronavirus) was first reported in 2012 in Saudi Arabia, caused several outbreaks in Middle Eastern countries and South Korea (Cui et al., 2019; da Costa et al., 2020; Majumder et al., 2017; Kim et al., 2017; Ramadan and Shaib, 2019; Killerby et al., 2020) , and had a case fatality rate of 25-40% (Majumder et al., 2014; Al Awaidy and Khamis, 2019; Mobaraki and Ahmadzadeh, 2019) . Recently, SARS-CoV-2, the etiologic agent of COVID-19, which was declared a pandemic on March 11, 2020 (Park, 2020) , was reported in late 2019 (Yang et al., 2020a) . As of August 27, 2020, COVID-19 caused >24,300,000 cases and >830,000 deaths worldwide (Medicine JHUSo, 2020) . SARS-CoV-2 and SARS-Co-V share 79% identity at the genomic level , and the surface glycoprotein S, which mediates cellular entry, is 76% identical at the amino acid level between the two (Ou et al., 2020; Walls et al., 2020) .

SARS-CoV and SARS-CoV-2 bind ACE2 (Walls et al., 2020; Hoffmann et al., 2020) , which is also the cellular receptor for a third human respiratory coronavirus, HCoV-NL63 (Jia et al., 2005; Hofmann et al., 2005) . HCoV-NL63 was first identified in a 7month-old baby with bronchiolitis and conjunctivitis in early 2004 (van der Hoek et al., 2004) and linked to common colds in children, the elderly, and immunocompromised individuals (Fielding, 2011) . HCoV-NL63 is distributed worldwide (Abdul-Rasool and Fielding, 2010) , occurs seasonally (Milewska et al., 2018) , and usually causes mild upper or lower respiratory infections (Abdul-Rasool and Fielding, 2010; Wang et al., 2020) , but was occasionally linked to severe infection or death (Konca et al., 2017; Mayer et al., 2016; Oosterhof et al., 2010) .

Biophysical assays indicate that SARS-CoV-2 binds ACE2 with a 10À20-fold higher affinity than SARS-CoV (Wrapp et al., 2020) . Xray crystallography showed that while the SARS-CoV receptorbinding motif has a sharp turn three-residue Pro-Pro-Ala motif, the receptor-binding region of SARS-CoV-2 has a four-residue Gly-Val-Glu-Gly motif that forms additional hydrogen bonds and establishes closer contact with ACE2 (Shang et al., 2020; Lanza et al., 2020) .

ACE2 is differentiated from other viral receptors in that it interfaces with a major endocrine vasoactive signaling pathway, the renin-angiotensin-aldosterone system (RAAS). RAAS is a vital hormonal mechanism that controls sodium-potassium balance, hemodynamic stability, and blood pressure (Muñoz-Durango et al., 2016; Chamsi-Pasha et al., 2014) , regulates neural, cardiovascular, and renal function (Li et al., 2017a) , and is involved in tissue remodeling (Kaparianos and Argyropoulou, 2011; Ames et al., 2019) and immune homeostasis (Crowley and Rudemiller, 2017; Rudemiller and Crowley, 2016) .

Angiotensinogen, produced primarily by the liver, is cleaved by renin, which is generated by the renal juxtaglomerular apparatus to form the inactive decapeptide angiotensin I (Ang I) (Dalan et al., 2020) . Angiotensin-converting enzyme (ACE), mostly synthesized in the lungs (Xiao et al., 2020) , cleaves Ang I to form the octapeptide angiotensin II (Ang II) (Perlot and Penninger, 2013; Oudit et al., 2003) . Angiotensin II acts via two G-protein-coupled receptors, Ang II receptor type 1 receptor (AT1R) and Ang II receptor type 2 receptor (AT2R) (Kuba et al., 2010) . Ang II binds with a high and equal affinity to AT1R and AT2R (Chow and Allen, 2016) . The two receptors differ in tissue distribution, the signaling pathways they activate, and their effects (Chow and Allen, 2016; Juillerat-Jeanneret, 2020; Abadir, 2011) . Most of the Ang II cardiovascular effects occur through AT1R; AT2R is less well understood (Abadir, 2011; Ichiki, 2013) . Ang II mediates aldosterone release from the adrenal gland, which results in sodium retention and increased blood pressure through AT1R (Dalan et al., 2020) . Ang II has additional effects that include vasoconstriction (Vukelic and Griendling, 2014; Benigni et al., 2010; Hubloue et al., 2004) , fibrosis (Chamsi-Pasha et al., 2014; Hamming et al., 2007; Marshall et al., 2004; Williams, 2001) , endothelial dysfunction (Gomolak and Didion, 2014) , inflammation (Gomolak and Didion, 2014) , and increased coagulation (Senchenkova et al., 2010; Verdecchia et al., 2020) .

The discovery of human ACE2 in 2000 by two independent genomics-based approaches (Tipnis et al., 2000; Donoghue et al., 2000) unveiled the existence of a counter-regulatory arm of the RAAS (Wang et al., 2012) . Even though both ACE and ACE2 are members of the RAAS (Danilczyk et al., 2003; Simoes and Teixeira, 2016) , they have distinct substrate specificities (Mendoza-Torres et al., 2015; Kuba et al., 2006) . Evolutionarily, ACE2 is a chimeric protein (Perlot and Penninger, 2013) . Its amino-terminal region harbors a metalloprotease catalytic domain that has a 42% identity with the metalloprotease catalytic domain of ACE (Donoghue et al., 2000) . Its carboxy-terminal region has a nearly 48% identity with (Zhang et al., 2001) . While ACE is located on human chromosome 17, ACE2 is on the X chromosome, possibly explaining some of the gender differences in the physiology of the RAAS (Oudit et al., 2003) .

A key role for ACE2 is to convert the octapeptide Ang II into the heptapeptide angiotensin-(1-7) ((Ang-(1-7)) (Turner et al., 2004) . ACE2 also cleaves a single residue from Ang I to generate angiotensin-(1-9) ((Ang-(1-9)) (Tipnis et al., 2000; Donoghue et al., 2000) , but its affinity for Ang II is 400-fold higher (Lazartigues et al., 2007) . Ang-(1-7) binds to the Mas receptor (Santos et al., 2003) and negatively regulates the RAAS (Kuba et al., 2010) causing vasodilation, cell growth inhibition (Lazartigues et al., 2007) , and exerting anti-proliferative (Wang et al., 2012) , anti-thrombotic (Fraga-Silva et al., 2008; Fraga-Silva et al., 2010) , and anti-arrhythmogenic effects (Simões e Silva et al., 2013) . Thus, the ACE2/Ang-(1-7)/Mas axis, as a negative regulator of the RAAS, opposes the ACE/Ang II/AT1R axis (Perlot and Penninger, 2013) .

After its discovery, ACE2 was thought to have a narrow tissue distribution (Lazartigues et al., 2007) , but subsequent studies documented its wide presence across many cell types (Borriello and Ianniello, 2020) . This is another characteristic that makes ACE2 unique among viral receptors. ACE2 is present in type II alveolar cells (Xu et al., 2020) and alveolar macrophages (Magrone et al., 2020; Kai and Kai, 2020) , salivary glands (Song et al., 2020) , the conjunctiva , the gastrointestinal tract , neurons, glial cells Bostanciklioglu, 2020) , adipose tissue (Gheblawi et al., 2020) , arterial and venous endothelial cells (Hamming et al., 2004) , arterial smooth muscle cells (Hamming et al., 2004) , cells in the heart, kidney, liver, (Patel et al., 2014) , uterus, vagina (Jing et al., 2020) , and the mucosa of the oral cavity (Xu et al., 2020) . In addition, several endocrine organs express ACE2, including cells of the pancreas , thyroid (Li et al., 2020a) , testis (Pal and Banerjee, 2020; Leal et al., 2009) , ovary (Reis et al., 2011; Pan et al., 2013) , adrenal glands (Li et al., 2020a) , pituitary (Wang et al., 2017; Alenina and Bader, 2019) , and the human placenta (Valdés et al., 2006) . ACE2 levels change in obesity, diabetes, heart disease, hypertension, and kidney and lung disease, which is another differentiating characteristic of this viral receptor (Hamming et al., 2007; Gheblawi et al., 2020; Sriramula et al., 2011; Úri et al., 2016; Moon, 2011) . It has been debated whether this relationship is causative or compensatory (Ingraham et al., 2020; Chu and Leung, 2009; Koka et al., 2008; Shi et al., 2010) . ACE2 is upregulated in the adipocytes of individuals with type 2 diabetes mellitus and obesity (Kruglikov and Scherer, 2020) and in several animal models of obesity (Patel et al., 2016a; Patel et al., 2016b; Gupte et al., 2008) . Acute hyperglycemia upregulates, and chronic hyperglycemia downregulates ACE2 . ACE2 expression also changes in malignancies (Fu et al., 2020; Yang et al., 2020b) , a finding that has implications for assessing the risk of severe COVID-19 in cancer patients (Dai et al., 2020; Chai et al., 2020; Yamaguchi et al., 2017) . Obesity, diabetes, and hypertension were recognized early during the COVID-19 pandemic among the conditions that increase the risk of severe disease and complications (Pan et al., 2020; Huang et al., 2020; Lippi et al., 2020; Singh et al., 2020; Caussy et al., 2020; Dietz and Santos-Burgoa, 2020; Kassir, 2020) . For example, in a retrospective cohort study of obese patients admitted to intensive care, COVID-19 severity increased with BMI (Simonnet et al., 2020) . Other conditions that increase COVID-19 severity include chronic respiratory diseases and cancer (Puig-Domingo et al., 2020; Ofori-Asenso et al., 2020) . Some of the same comorbidities were identified during the MERS Kulcsar et al., 2019; Alqahtani et al., 2018; Assiri et al., 2013) and SARS (Chan-Yeung and Xu, 2003; Yang et al., 2006; Gu and Korteweg, 2007) outbreaks as risk factors for more severe coronavirus disease.

By increasing viral internalization, ACE2 upregulation may enhance the viral load and increase disease severity. At the same time, ACE2 is protective in experimental models of lung failure (Kuba et al., 2006) , and its downregulation accelerates tissuespecific pathologies. In a mouse model of acute respiratory distress syndrome, Ace2 deficiency worsened acute lung injury, increased vascular permeability, caused edema and inflammatory infiltrates, and impaired lung function. ACE deficiency on this genetic background, or treatment with exogenous ACE2 protein, markedly protected from acute lung injury . SARS-CoV and the SARS-CoV spike protein downregulated ACE2 lung expression without changing ACE levels, indicating that the infected wild-type mice resemble ace2 knockout mice . It appears that during SARS-CoV or SARS-CoV-2 infection, ACE2 downregulation decreases signaling through the ACE2-angiotensin-(1-7)-Mas receptor (Verdecchia et al., 2020; Kai and Kai, 2020; Li et al., 2020b) and amplifies signaling through the ACE-angiotensin II-AT1R receptor axis (Kai and Kai, 2020; Deshotels et al., 2014) . Ang II is known to increase IL-6 expression in a dose-dependent manner (Funakoshi et al., 1999; Senchenkova et al., 2019; Skurk et al., 2004) . The other two axes activated by ACE2 downregulation are the ACE2/DABK/bradykinin/B1R axis and the complement signaling pathways (Mahmudpour et al., 2020) . ACE2 cleaves a terminal residue in des-Arg 9 bradykinin (DABK) (Sodhi et al., 2018) , an inflammatory factor in the lung, leading to its inactivation. Reduced ACE2 activity would, therefore, cause increased DABK activity and inflammation (Mahmudpour et al., 2020) .

A feature that is shared by several medical conditions that increase COVID-19 severity is the presence of low-grade systemic inflammation (Chiappetta et al., 2020; Zabetakis et al., 2020; Ciornei, 2020) . In several studies, elevated IL-6 was associated with increased COVID-19 severity or case fatality rate Ulhaq and Soraya, 2020; Aziz et al., 2020) . Obesity is an established cause of low-grade systemic inflammation (Ellulu et al., 2017; Xu, 2013; O'Rourke, 2009; Calder et al., 2011) , which contributes to a heightened risk of several chronic degenerative diseases, including hypertension (Chamarthi et al., 2011) , cardiovascular disease (Lopez-Candales et al., 2017; Guarner and Rubio-Ruiz, 2015; Moore, 2019) , and diabetes (Qu et al., 2014; Akbari and Hassan-Zadeh, 2018; Pitsavos et al., 2007) .

Another observation about patient groups at risk for severe COVID-19 is the presence of underlying medical conditions characterized by endothelial dysfunction. A consequence of inflammation (Castellon and Bogdanova, 2016; Steyers and Miller, 2014; Huang and Vita, 2006; Daiber et al., 2017) , endothelial dysfunction also promotes and maintains inflammation (Hadi et al., 2005; Sun et al., 2019) and was described in aging (Higashi et al., 2012) and chronic degenerative conditions such as diabetes mellitus (Shi and Vanhoutte, 2017; Kaur et al., 2018) , hypertension (Higashi et al., 2012; Ghiadoni et al., 2012; Bernatova, 2014) , and obesity (Engin, 2017; Virdis et al., 2019; Bhatta et al., 2017) . Other viruses that cause endothelial activation include Ebola and Marburg viruses, dengue virus, hantaviruses, and influenza A virus (Spiropoulou and Srikiatkhachorn, 2013; Armstrong et al., 2013) . ACE2 protects endothelial function (Li et al., 2017b; Li et al., 2013; Paz Ocaranza et al., 2020) and exerts anti-inflammatory effects (Zhang et al., 2015; Rodrigues Prestes et al., 2017) , and ACE2/ACE imbalances accelerate endothelial dysfunction and worsen the progression of vascular disease (Tikellis and Thomas, 2012; Olkowicz et al., 2015) . With a surface comparable to that of six tennis courts, and a total length of $100,000 km, or $2.5 times the Earth circumference (Higashi et al., 2012; Higashi et al., 2009) , the human vascular endothelium is a large (Higashi et al., 2012; Anggård,1990; Talman and Kivelä, 2018) , diffuse (Anggård, 1990; Henderson and Henderson, 1995; Krüger-Genge et al., 2019) , and very active (Baumgartner-Parzer and Waldhäusl, 2001) endocrine organ. Vascular endothelium activation and damage occur as part of COVID-19 (Varga et al., 2020; De Lorenzo et al., 2020; Escher et al., 2020; Huertas et al., 2020) , resulting in a microvascular injury syndrome that may create a procoagulant state (Magro et al., 2020; O'Sullivan et al., 2020) and explain the systemic nature of the disease.

ACE2-Ang-(1-7)-Mas signaling induces antithrombotic effects (Verdecchia et al., 2020; Fraga-Silva et al., 2010) as a result of the Mas-mediated nitric oxide release from platelets (Fraga-Silva et al., 2008; Fang et al., 2013) . ACE2 down-regulation in COVID-19 (Kai and Kai, 2020; Kuba et al., 2005; Vaduganathan et al., 2020) , induced by internalization of the virus-receptor complex, could be particularly detrimental in individuals with already existing ACE2 deficiency and further dysregulate the balance between the ACE-Ang II-AT1R and the ACE2-Ang-(1-7)-Mas axes (Verdecchia et al., 2020) . It was proposed that two hits to the RAAS could drive COVID-19 progression. The first one is the chronic inflammation that activates the ACE-Ang II axis, and the second one is the viral infection, which inactivates the ACE2-Ang-(1,7) axis (Tseng et al., 2020) . This imbalance may explain the systemic coagulation and thrombotic events reported in COVID-19 patients (Middeldorp et al., 2020) . The cumulative incidence of thrombotic complications in patients with COVID-19 in intensive care units reached 31-49% in one study, even among those who received pharmacological thromboprophylaxis (Klok et al., 2020a; Klok et al., 2020b) . In another study that examined consecutive patients who died of COVID-19, 58% had deep venous thrombosis (Wichmann et al., 2020) . Studies of pregnant women with COVID-19 documented an increased prevalence of decidual arteriopathy (Shanes et al., 2020) and fetal vascular thrombosis (Baergen and Heller, 2020) .

SARS-CoV-2 binding to a cellular receptor that belongs to an endocrine signaling pathway, and the subsequent dysregulation in inflammation Mehta et al., 2020; Kadkhoda, 2020) , endothelial function (Bermejo-Martin et al., 2020) , and coagulation , define the framework that underlies COVID-19 pathogenesis. Not only does SARS-CoV-2 affect all three of these domains by inducing an inflammatory cytokine storm (Mehta et al., 2020; Ye et al., 2020; Sun et al., 2020) , multiorgan endothelial dysfunction (Varga et al., 2020) , and thrombotic complications (Giannis et al., 2020; Frydman et al., 2020; Vivas et al., 2020) , but perturbations in these three major axes are also intimately interconnected. For example, chronic inflammation may result in endothelial dysfunction (Castellon and Bogdanova, 2016) and thrombotic events (Aksu et al., 2012; Branchford and Carpenter, 2018; Prasad et al., 2016) , endothelial dysfunction promotes thrombosis (Yau et al., 2015) , and acute thrombosis can accelerate endothelial dysfunction (Kashyap et al., 2001 ). An acute need in the wake of the current pandemic is to better understand the physiological interconnectedness among these three major pathways, interrogate their relative contribution to pathogenesis, and unveil the manner and the extent to which SARS-CoV-2 individually modulates each of them. This will provide a valuable set of tools indispensable for understanding a novel viral infection that is fundamentally different, and markedly more complex, than all the infectious diseases that we have studied to date.

The frail renin-angiotensin system

Understanding human coronavirus HCoV-NL63

IL-6 signalling pathways and the development of type 2 diabetes

Inflammation-induced thrombosis: mechanisms, disease associations and management

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Oman: current situation and going forward

ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models

Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study

The renin-angiotensin-aldosterone system and its suppression

The endothelium-the body's largest endocrine gland?

Endothelial activation and dysfunction in the pathogenesis of influenza A virus infection

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

Elevated interleukin-6 and severe COVID-19: a metaanalysis

Placental pathology in Covid-19 positive mothers: preliminary findings

The endothelium as a metabolic and endocrine organ: its relation with insulin resistance

Angiotensin II revisited: new roles in inflammation, immunology and aging

COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction

Endothelial dysfunction in experimental models of arterial hypertension: cause or consequence?

Obesity-induced vascular dysfunction and arterial stiffening requires endothelial cell arginase 1

Practical recommendations for the management of diabetes in patients with COVID-19

COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach

Severe acute respiratory syndrome coronavirus 2 is penetrating to dementia research

The role of Inflammation in venous thromboembolism

Dietary factors and low-grade inflammation in relation to overweight and obesity

Chronic inflammatory diseases and endothelial dysfunction

Obesity is associated with severe forms of COVID-19

Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis

Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans

Angiotensin-converting enzyme 2 as a therapeutic target for heart failure

Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)

SARS: epidemiology

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

COVID-19 and the role of chronic inflammation in patients with obesity

Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease

Angiotensin II in type 2 diabetes mellitus

Prevention of severe coronavirus disease 2019 outcomes by reducing low-grade inflammation in high-risk categories

Severe acute respiratory syndrome (SARS)

Immunologic effects of the renin-angiotensin system

Origin and evolution of pathogenic coronaviruses

The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century

A profiling analysis on the receptor ACE2 expression reveals the potential risk of different types of cancers vulnerable to SARS-CoV-2 infection

Targeting vascular (endothelial) dysfunction

The ACE-2 in COVID-19: foe or friend?

A story of two ACEs

Systemic endothelial dysfunction: a common pathway for COVID-19, cardiovascular and metabolic diseases

Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism

Obesity and its implications for COVID-19 mortality

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Obesity and inflammation: the linking mechanism and the complications

Endothelial dysfunction in obesity

Severe COVID-19 infection associated with endothelial activation

Angiotensin 1-7 and mas decrease thrombosis in Bdkrb2-/-mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation

Human coronavirus NL63: a clinically important virus?

The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets

ACE2 activation promotes antithrombotic activity

Coagulation status and venous thromboembolism risk in African Americans: a potential risk factor in COVID-19

Expressions and significances of the angiotensinconverting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19

Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells

SARS-CoV-2 receptor and regulator of the reninangiotensin system: celebrating the 20th anniversary of the discovery of ACE2

Hypertension and endothelial dysfunction: therapeutic approach

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Angiotensin II-induced endothelial dysfunction is temporally linked with increases in interleukin-6 and vascular macrophage accumulation

Pathology and pathogenesis of severe acute respiratory syndrome

Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease

ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet

Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): a perpetual challenge

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

The emerging role of ACE2 in physiology and disease

The endocrine function of the vascular endothelium

Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

Endothelial function and oxidative stress in cardiovascular diseases

Endothelial dysfunction and hypertension in aging

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

Effects of systemic inflammation on endothelium-dependent vasodilation

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Endogenous angiotensin II in the regulation of hypoxic pulmonary vasoconstriction in anaesthetized dogs

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Regulation of angiotensin II receptor expression

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Understanding the renin-angiotensin-aldosterone-SARS-CoV-Axis: a comprehensive review

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

Potential influence of COVID-19/ACE2 on the female reproductive system

The other angiotensin ii receptor: AT(2)R as a therapeutic target

COVID-19: an Immunopathological View

Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19

Local renin-angiotensin II systems, angiotensinconverting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome

Acute arterial thrombosis causes endothelial dysfunction: a new paradigm for thrombolytic therapy

Risk of COVID-19 for patients with obesity

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Middle East Respiratory Syndrome coronavirus transmission

Middle East Respiratory Syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis

Angiotensin II upregulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway

The first infant death associated with human coronavirus NL63 infection

Vascular endothelial cell biology: an update

The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Lessons from SARS: control of acute lung failure by the SARS receptor ACE2

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection

Covid-19: the renin-angiotensin system imbalance hypothesis

The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases

The role of angiotensin-(1-7) receptor Mas in spermatogenesis in mice and rats

ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats

The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases

Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV

Severe acute respiratory syndrome coronavirus 3C-like protease-induced apoptosis

Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis

ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection

Linking chronic inflammation with cardiovascular disease: from normal aging to the metabolic syndrome

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target-a perspective

COVID-19 cytokine storm: the anger of inflammation

Estimation of MERS-coronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: insights from publicly available data

Nosocomial amplification of MERS-coronavirus in South Korea

Angiotensin II and the fibroproliferative response to acute lung injury

Fatal outcome of human coronavirus NL63 infection despite successful viral elimination by IFN-alpha in a patient with newly diagnosed ALL

COVID-19: consider cytokine storm syndromes and immunosuppression

ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Entry of human coronavirus NL63 into the cell

Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: a cross-sectional study

ACE2 and angiotensin-(1-7) in hypertensive renal disease

Targeting inflammation in CVD: advances and challenges

Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in endorgan damage during arterial hypertension

Inflammation in obesity-related diseases

Endothelial cells orchestrate COVID-19 coagulopathy

Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis

Perspectives for angiotensin profiling with liquid chromatography/mass spectrometry to evaluate ACE/ACE2 balance in endothelial dysfunction and vascular pathologies

Fatal lower respiratory tract disease with human corona virus NL63 in an adult haematopoietic cell transplant recipient

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

The role of ACE2 in cardiovascular physiology

COVID-19 and the endocrine system: exploring the unexplored

Angiotensin-converting enzymes play a dominant role in fertility

Association of public health interventions with the epidemiology of the COVID-19 Outbreak in Wuhan, China

Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)

From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension

ACE2/Ang 1-7 axis: a critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity

ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity

Counterregulatory renin-angiotensin system in cardiovascular disease

ACE2-from the renin-angiotensin system to gut microbiota and malnutrition

Association between low-grade systemic inflammation and type 2 Diabetes mellitus among men and women from the ATTICA study

Coronary endothelial dysfunction is associated with increased risk of venous thromboembolism

COVID-19 and endocrine diseases. A statement from the

IL-6 in diabetes and cardiovascular complications

Middle East respiratory syndrome coronavirus (MERS-CoV): a review

Angiotensin-(1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary

Simoes e Silva AC. The anti-inflammatory potential of ACE2/angiotensin

/mas receptor axis: evidence from basic and clinical research

Interactions between the immune and the reninangiotensin systems in hypertension

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

The molecular biology of SARS coronavirus

Angiotensin II-mediated microvascular thrombosis

Novel role of T cells and IL-6 (Interleukin-6) in angiotensin II-induced microvascular dysfunction

Placental Pathology in COVID-19

Structural basis of receptor recognition by SARS-CoV-2

Macro-and microvascular endothelial dysfunction in diabetes

Angiotensin-converting enzymes and drug discovery in cardiovascular diseases

ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis

ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis

High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation

Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations

Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB

Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration

Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2

The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome

ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension

Endothelial dysfunction in chronic inflammatory diseases

Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide

Cytokine storm intervention in the early stages of COVID-19 pneumonia

Cardiomyocyte-endothelial cell interactions in cardiac remodeling and regeneration

Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Two hits to the renin-angiotensin system may play a key role in severe COVID-19

ACE2: from vasopeptidase to SARS virus receptor

Interleukin-6 as a potential biomarker of COVID-19 progression

Circulating ACE2 activity correlates with cardiovascular disease development

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies

Identification of a new human coronavirus

Endothelial cell infection and endotheliitis in COVID-19

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

Microvascular endothelial dysfunction in patients with obesity

Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology

Angiotensin II, from vasoconstrictor to growth factor: a paradigm shift

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Role of ACE2 in diastolic and systolic heart failure

Insufficient hypothalamic angiotensin-converting enzyme 2 is associated with hypertension in SHR rats

Discovery of a subgenotype of human coronavirus NL63 associated with severe lower respiratory tract infection in China

Autopsy findings and venous thromboembolism in patients with COVID-19

Angiotensin II and the pathophysiology of cardiovascular remodeling

Covid-19 and the digestive system

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

ACE2: the key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel?

Obesity and metabolic inflammation

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Angiotensinconverting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma

Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19

Endothelial cell control of thrombosis

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

COVID-19: the inflammation link and the role of nutrition in potential mitigation

Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys

ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response

Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms